The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), ...

Fresenius Kabi, an operating company of Fresenius, announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent, product-specific billing code for Otulfi® ...

Living with psoriasis presents unique challenges, but with the right skincare routine, you can maintain healthy skin.

The EC has granted marketing authorisation for Johnson & Johnson's (J&J) Tremfya to treat adults with ulcerative colitis (UC) ...

This came after the firm presented their proposal for the manufacturing and marketing of Roflumilast Cream 0.3% w/w for the ...

A plain language summary for patients explains there were no differences in safety outcomes between adalimumab-adbm and the ...

Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 - MoonLake Immunotherapeutics (Nasdaq: MLTX), a clinical-stage biotechnology company ...

MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...